Related Experiment Video
Updated: May 4, 2026
Optimization of the Retinal Vein Occlusion Mouse Model to Limit Variability
Published on: August 6, 2021
Toward postnatal reversal of ocular congenital malformations
Insights
Aniridia, a severe vision disorder, may be treatable. Early postnatal topical ataluren reversed congenital eye malformations in mice by manipulating the PAX6 gene, offering hope for therapeutic interventions.
Area of Science:
- Ophthalmology
- Developmental Biology
- Genetics
Background:
- Aniridia is a severe panocular disorder impacting early vision.
- Mutations in the PAX6 gene, crucial for eye and CNS development, cause most aniridia cases.
Purpose of the Study:
- To investigate the potential of ataluren in reversing congenital eye malformations associated with PAX6 gene dysfunction.
Main Methods:
- Early postnatal topical administration of an ataluren-based formulation in a mouse model.
- Observation of effects on congenital malformations in the postnatal mouse eye.
Main Results:
- Ataluren administration successfully reversed congenital malformations in the postnatal mouse eye.
- Demonstrated that manipulation of PAX6 after birth can lead to corrective tissue remodeling.
Conclusions:
- Early postnatal topical ataluren shows promise as a therapeutic strategy for aniridia.
- This approach may offer a new paradigm for treating major congenital eye defects.
Abstract:
Aniridia is a panocular disorder that severely affects vision in early life. Most cases are caused by dominantly inherited mutations or deletions of the PAX6 gene, which encodes a transcription factor that is essential for the development of the eye and the central nervous system. In this issue of the JCI, Gregory-Evans and colleagues demonstrate that early postnatal topical administration of an ataluren-based formulation reverses congenital malformations in the postnatal mouse eye, providing evidence that manipulation of PAX6 after birth may lead to corrective tissue remodeling. These findings offer hope that ataluren administration could be a therapeutic paradigm applicable to some major congenital eye defects.
